

48. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. *Am J Hypertens* 1992; 5: 95-110
49. Hansen JF, Hagerup L, Sigurd B, et al. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. *Am J Cardiol* 1997; 79: 738-41
50. Nayler WG. Amlodipine. Berlin, Heidelberg: Springer-Verlag, 1993
51. Urquhart J. Ascertaining how much compliance is enough with out-patient antibiotic regimens. *Postgrad Med J* 1992; 68 Suppl. 3: 49-59
52. McMurray J, Murdoch D. Calcium-antagonist controversy: the long and short of it? *Lancet* 1997; 349: 585-6
53. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. *JAMA* 1997; 277: 739-45
54. Staessen JA, and others for the Systolic Hypertension in Europe (Syst-Eur) Trial investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. *Lancet* 1997; 350: 757-63

Correspondence and reprints: Professor *Thomas F. Lüscher*, University Hospital Zurich, Department of Internal Medicine, Cardiology, Rämistrasse 100, CH-8091 Zurich, Switzerland.

Errata

Vol. 54, No. 5, page 789: In column 1, the second paragraph should read: '*ECG studies conducted during therapeutic trials of mibefradil in patients with hypertension or stable angina pectoris have reported either a slight decrease^[53,56,57,63] or no change^[50] in mean corrected QT (QTc) interval. In an integrated safety analysis, mean QTc interval decreased slightly at the recommended dosages of 50 or 100mg daily.^[66,67]*'.

[Brogden RN, Markham A. Mibefradil: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris. *Drugs* 1997 Nov; 54 (5): 774-93]

Vol. 54, No. 6, page 903: In the list of reviewers of the manuscript, the following name should be added: **B. Tardy-Poncet**, Laboratoire d'Hémostase, Département d'Hématologie, Hôpital Nord, CHU de Saint Etienne, France.

[Wilde MI, Markham A. Danaparoid: a review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. *Drugs* 1997 Dec; 54 (6): 903-24]

Vol. 55, No. 2, page 203: In section 5.3.1, equation 6 should read:

$$\text{'Volume of 0.3 mol/L THAM (ml) = bodyweight (kg) } \times \text{ base deficit (mEq/L)'}.$$

[Nahas GG, Sutin KM, Fermon C, et al. Guidelines for the treatment of acidaemia with THAM. *Drugs* 1998 Feb; 55 (2): 191-224]

Vol. 55, No. 2, page 318: In column 2, the second sentence of the fifth paragraph should read: '*... in patients who remain symptomatic while receiving low to moderate doses of inhaled corticosteroids.^[82,83]*'.

page 319: In the second paragraph of section 6, the fifth sentence should read: '*... with a regular regimen of low to moderate doses of inhaled corticosteroids and short-acting β_2 -agonists as needed.^[82,83]*'.

page 322: Reference 83 should read: '*83. National Asthma Education and Prevention Programme. Expert panel report II: guidelines for the diagnosis and management of asthma. Bethesda: NHLBI Information Center, 1997*'.

[Bartow RA, Brogden RN. Formoterol: a review of its pharmacological properties and therapeutic efficacy in the management of asthma. *Drugs* 1997 Feb; 55 (2): 303-22]